When does 4DX.AX stock report earnings and why does it matter?

4DX.AX stock reports around 27 Feb 2026. The report matters because management guidance, revenue growth and subscription uptake for XV Technology will influence near-term cash flow and valuation perceptions.

What is Meyka AI's short-term forecast for 4DX.AX stock?

Meyka AI's model projects a monthly level of **A$3.33** and a quarterly target of **A$5.04**, with a 12-month forecast of **A$4.12**. Forecasts are model-based projections and not guarantees.

What are the main valuation concerns for 4DMedical (4DX.AX)?

Primary concerns are a high price-to-sales ratio (~**486.60**), negative earnings, and a current ratio under **1.00**, which together signal a premium valuation versus present revenue and operating losses.

How should investors use the upcoming earnings for 4DX.AX stock?

Use the earnings release to confirm revenue trends, margin trajectory and cash runway. Look for concrete sales contracts, US commercial updates, or guidance improvement before adjusting a position in 4DX.AX stock.

AU Stocks

Market closed: 4DX.AX 4DMedical (ASX) rises 8.40% to A$4.00 ahead of 27 Feb 2026 earnings: watch guidance

ByDanny Kontos February 27, 2026

4DX.AX stock jumped 8.40% to A$4.00 on 27 Feb 2026 as investors positioned ahead of an imminent earnings update. The move came on 22,604,962.00 shares traded and lifted the year range after recent strength. Earnings are due around 27 Feb 2026 and the company’s revenue and guidance will be the key near-term catalysts for investors in Australia’s ASX-listed 4DMedical Limited.